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Introduction:  Self-reported  measles  vaccination  coverage  is  frequently  used  to  inform  vaccination  strate-
gies in  resource-poor  settings.  However,  little  is  known  to  what  extent  this  is  a reliable  indicator  of
underlying  seroprotection,  information  that could  provide  guidance  ensuring  the  success  of  measles
control  and  elimination  strategies.
Methods:  As  part  of  a study  exploring  HIV infection  and  measles  susceptibility,  we  conveniently  sampled
consenting  HIV-uninfected  patients  presenting  at the  HIV voluntary  counselling  and  testing  centre,  and
HIV-infected  patients  presenting  for regular  care,  in  Chiradzulu  district  hospital,  Malawi,  between  January
and  September  2012.
Results:  A total of  2106  participants  were  recruited  between  January  and  September  2012,  three  quarters
of whom  were  HIV  positive.  Vaccination  cards  were available  for just  7  participants  (0.36%).  91.9%  of
participants  were  measles  seropositive.
Older age  (OR =  1.11  per  year  increase  in  age;  95%CI:  1.09–1.14)  and  being  female  (OR  =  1.90;  95%CI:
1.26–2.87)  were  both  associated  with  signiﬁcantly  increased  odds  for seroprotection.  Prior  vaccination
history  was  associated  with  lower  odds  (Odds  Ratio  (OR)  =  0.44;  95%  conﬁdence  interval  (CI):  0.22–0.85)
for  conﬁrmed  seropositivity.  Previous  measles  infection  was  not  signiﬁcantly  associated  with  seropro-
tection  (OR  =  1.31;  95%CI:  0.49–3.51).
Protection  by  history  and serological  status  were  concordant  for 64.3%  of participants  <35 years  old.
However,  analysis  by  age  group  reveals  important  differences  in  concordance  between  the  ages,  with  a
greater degree  of discordance  among  younger  ages.
Vaccination  and/or  infection  history  as a predictor  of seropositivity  was  75.8%  sensitive,  but  just  10.3%
speciﬁc.
Conclusion:  Reported  vaccination  and  previous  infection  were  poor  predictors  of  seropositivity,  suggest-
ing these  may  be unreliable  indicators  of seroprotection  status.  Such  serosurveys  may  be indicated
in  similar  settings  in  which  overestimation  of  the  proportion  of  seroprotected  individuals  could  have
important  ramiﬁcations  if  used  to guide  vaccination  strategies.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Measles vaccination was estimated to prevent 15.6 million
eaths between 2000 and 2013, although approximately 145,000
eaths still occur each year, mostly in children under 5 years of
ge [1]; more than 95% of these deaths occur in resource-poor
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settings in Africa and Asia [2]. In recent years, enormous
progress towards measles elimination has been made in some
of the most affected countries, leading to a huge reduction in
measles-related morbidity and mortality [2]. However a resur-
gence of measles in some sub-Saharan African countries has been
documented [3].Malawi introduced one dose of measles containing vaccine
(MCV) for infants at (or soon after) 9 months of age into the rou-
tine immunization programme in 1979 [4]. The routine programme
was supplemented with a non-selective catch-up campaign
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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argeting all children 9 months to 14 years of age in 1998, regard-
ess of prior vaccination history. Follow-up campaigns targeting
hildren 9–59 months were conducted in 2002, 2005 and 2008.
n 2010, a Demographic and Health Survey estimated that 93% of
hildren 12–23 months of age had received MCV  [5].
A large and unexpected measles outbreak occurred in Malawi
n 2010, during which a total of 134,039 cases and 304 deaths were
eported [4]. 42% of the reported cases were under 5 years of age
nd 30% of cases were reported in children aged 5 to 14 years and
8% in adults (aged 15 years and older). A vaccination coverage
urvey after the reactive vaccination campaign targeting children
 months to 14 years of age in Chiradzulu district showed 98.0%
overage (95% CI: 97.4–98.5%) [4] by card conﬁrmation and oral
eporting.
As part of a larger study on measles serological protection in HIV
nfected and uninfected individuals in Chiradzulu district [6], we
ollected data on measles vaccination and disease history. Our aim
as to explore self-reported measles protective status, and com-
aring this with measles serological result, in order to inform local
ssessments of vaccine coverage and provide important guidance
n how these assessments could be improved to ensure control
trategies are successful.
. Methods
A facility-based study was conducted to assess differences in
evels of measles antibodies between HIV-infected and uninfected
ndividuals in Chiradzulu district, Malawi [6]. A secondary objective
f this study was to correlate self-reported measles protective sta-
us with measles serological result. The sample size was  calculated
ased on the primary objective of the study.
Eligible participants were those aged 18 months and older
ho were able to understand the patient information sheet and
ho gave informed consent to participate. All individuals meeting
he inclusion criteria attending voluntary counselling and testing
ervices or presenting for follow-up care at Chiradzulu District
ospital were invited to participate. A convenient sample of all
onsecutive individuals consenting to participate who presented
uring the study period was enrolled until the desired sample size
as reached.
.1. Sample collection and processing
Venous blood samples were collected from each participant by a
ualiﬁed phlebotomist. Serum samples were extracted and stored
t −20 ◦C until tested for measles IgG antibodies at the National
nstitute for Communicable Diseases (NICD) in Johannesburg, South
frica.
Quantitative measurement of measles IgG was performed
sing an enzyme linked immunosorbent assay (ELISA; Enzyg-
ost Anti-Measles IgG, Dade Behring, Germany). The assay was
alibrated against the international reference preparation. Kit
ependent parameters were used to express results as an anti-
ody concentration (mIU/ml) derived from the optical density
OD) according to the manufacturer’s instructions. Samples were
ategorized as seropositive (IgG titre > 330 mIU/ml), seronega-
ive (IgG < 120 mIU/ml) and equivocal (IgG titre 120–330 mIU/ml).
quivocal samples were retested and classiﬁed accordingly. Those
till equivocal after retest were considered negative as equivocal
esults are below the 330 mIU/ml protection threshold.
.2. InterviewInformation on demographic characteristics, previous measles
accination and previous measles infection were collected from
ach participant using a structured questionnaire administered by33 (2015) 4554–4558 4555
trained interviewers in Chichewa, the local language. When avail-
able, vaccination cards were used to complement recall of previous
vaccination.
Following the verbal histories, participants were categorized
as “protected” (reported previous vaccination and/or infection),
“susceptible” (reported no previous vaccination and no previous
infection), and ‘unknown’ (missing information for previous vacci-
nation and previous disease).
“Protected” participants were categorized as protected by vac-
cination if protection was  established from vaccination only; or
as protected by disease if they declared a past measles infection
independently of reported vaccination.
2.3. Data collection
Anonymized data were double-entered into an EpiData
database mask (EpiData Association 2010). Data were cleaned and
exported to Stata 13.0 (College Station, TX, USA) for analysis.
2.4. Statistical analysis
MCV  seroprevalence and descriptive analysis of measles anti-
bodies included all study participants with known titres (analysis
A). In a second analysis (analysis B), logistic regression models were
used to calculate the odds of seroprotection according to measles
vaccination and infection history, age, sex and HIV status in univari-
able and multivariable models. In these analyses only participants
aged <35 years of age for whom a measles history questionnaire
was completed were included. Participants aged ≥35 years old were
excluded from this analysis because they had not been targeted by
MCV  vaccination activities.
Serological results were log-transformed to obtain a more nor-
mal  distribution. Differences on geometric mean titres (GMTs)
amongst groups were analysed using linear regression.
Additionally, the sensitivity, speciﬁcity, positive predictive
value (PPV) and negative predictive value (NPV) of reported vac-
cination status/previous infection were calculated using measles
seropositivity as the ‘gold-standard’ reference measure.
2.5. Ethical considerations
This study adhered to the principles that govern biomedi-
cal research involving human subjects. The study protocol was
approved by the National Health Sciences Research Committee
of Malawi. The Declaration of Helsinki was  followed, aiming to
provide assurance that the rights, integrity, and conﬁdentiality of
trial subjects were protected.
Informed consent was sought from the study participants or
from their parent/guardian if they were under the age of 18 years.
Participation in the study was  voluntary, entailing no obvious ben-
eﬁts or risks.
3. Results
In total 2106 participants were recruited from the District
Hospital in Chiradzulu district, Malawi, between January and
September 2012. A measles serological result and complete ques-
tionnaire are available for 1929 individuals. The mean age of
enrolled participants was  36.9 years (median = 37) with a sex ratio
of male/female of 0.6. There were only 9 participants in the 18
months to 4 years age group. On interview, only 7 participants
(0.36%) showed a vaccination card to the interviewer. Three quar-
ters of the participants were HIV positive (Table 1).
Overall, 61.8% of participants (1192) reported having received
a measles vaccine. Reported measles vaccination was  high, even
amongst participants aged ≥35 years old with no opportunities
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Table  1
Participant characteristics.
Characteristic N (%) GMT* in mIU/ml (95% CI)
Measles serological status
Seropositive 1772 (91.9) 2807 (2693–2926)
Seronegative 157 (8.1) 138 (122–157)
Age
18  m–14 y 95 (4.9) 395 (298–525)
15–29 y 388 (20.1) 1207 (1055–1382)
30–44 y 915 (47.4) 2709 (2534–2896)
≥45 y 531 (27.5) 3223 (2990–3475)
Sex
Male 702 (36.4) 1964 (1785–2160)
Female 1224 (63.5) 2345 (2198–2502)
HIV  status
Negative 507 (26.3) 1832 (1642–2045)
Positive 1422 (73.7) 2344 (2204–2492)
Vaccination history
Vaccinated 1.192 (61.8) 2127 (1980–2285)
Not  vaccinated 311 (16.1) 2508 (2205–2854)
Unknown 426 (22.1) 2182 (1968–2419)
Previous measles infection
Yes 325 (16.9) 3182 (2862–3538)
No  1604 (83.2) 2038 (1918–2165)
* Geometric mean titre.
Table 2
Measles seroprevalence and geometric mean titre (GMT) by category, participants
<35 years old.
Category N N protected (%) GMT  (95% CI)
Unprotected 144 132 (91.7) 1733 (1395–2154)
Protected by vaccination 413 317 (76.7) 1037 (902–1193)
Protected by disease 104 96 (92.3) 2670 (2118–3441)
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Table 3
Factors associated with seropositivity in participants <35 years of age.
Characteristic Univariable OR
(95% CI)
Multivariable OR
(95% CI)
Measles verbal history
Unprotected Ref Ref
Protected by vaccination 0.30 (0.16–0.57) 0.44 (0.22–0.85)
Protected by disease 1.09 (0.43–2.77) 1.31 (0.49–3.51)
Unknown status 0.58 (0.27–1.23) 0.24 (0.29–1.14)
Age
18  m–14 y Ref Ref
15–33 y 5.72 (3.62–9.01) 4.77 (2.94–7.73)
34–44 y 43.23 (22.55–82.91) 39.64 (20.35–77.22)
≥45 y 59.23
(27.37–128.19)
53.17
(24.24–116.65)
Sex
Male Ref Ref
Female 1.96 (1.35–2.85) 1.90 (1.26–2.87)
HIV  status
Negative Ref Ref
Positive 0.82 (0.56–1.20) 0.60 (0.38–0.93)
N = 808 in univariable and multivariable analysis.Unknown status 147 127 (86.4) 1378 (1130–1679)
All  808 672 (83.2) 1354 (1229–1491)
or measles vaccination. 16.9% of participants (n = 325) reported a
revious measles infection and 87.4% of these (n = 284) reported a
easles infection within the previous 24 months. A total of 494
articipants (25.6%) reported a measles infection in a member of
heir household within the previous 24 months.
From serological results, 91.9% of participants (n = 1772) were
lassiﬁed as measles seropositive. Mean GMT  was  2082 IU/ml
range 8–18,479). GMTs were signiﬁcantly higher with increased
ge and females had a higher GMT  than males.
A measles infection within the last 24 months was not associ-
ted with higher GMT  than those that reported measles infection
onger in the past (p = 0.504). However, reporting a measles infec-
ion within the household in the previous 24 months was  strongly
ssociated with a higher GMT, even after adjusting for age, sex and
IV status (p = 0.007).
.1. Measles history and serological status amongst participants
35 years of age
Amongst participants aged <35 years of age, considered as hav-
ng had vaccination opportunities, over three-quarters of those
ategorized as protected by vaccination, and over 90% of those that
eported a previous measles infection, were seropositive (Table 2).
MTs were signiﬁcantly higher amongst the protected by dis-
ase group than the unprotected group (2670 vs. 1733, p = 0.012).
owever, GMTs were signiﬁcantly lower in the vaccinated group
ompared to the unprotected. There were no signiﬁcant differ-
nces in GMTs in relation to the number of measles doses received
p = 0.833).
Prior vaccination history was associated with lower odds (odds
atio (OR) = 0.44; 95% conﬁdence interval (CI): 0.22–0.85) for con-
rmed seropositivity (Table 3). Having declared a previous measlesFig. 1. Proportion of participants <35 years of age protected by history and/or sero-
logical status, according to age group.
infection was  associated with higher odds for seroprotection
(OR = 1.31; 95% CI: 0.49–3.51), however this was not statistically
signiﬁcant. Older age (OR = 1.11 per year increase in age; 95% CI:
1.09–1.14) and being female (OR = 1.90; 95% CI: 1.26–2.87) were
both associated with signiﬁcantly increased odds for seroprotec-
tion.
3.2. Validity of measles protection history as a predictor of
seropositivity
Protection by verbal history was higher in the <15 years old
(91.6%; 95% CI: 83.9–95.8%) and lowest in the 15–29 years old group
(59.6% protected; 95% CI: 55.7–63.3%). However serological results
showed that the young population has the lowest proportion of
seropositivity (47.4%; 95% CI: 37.4–57.6).
Protection by history and serological status were concordant
for 64.3% of participants <35 years old. However, analysis by age
group reveals important differences in concordance between the
ages, with a greater degree of discordance among younger ages
(Fig. 1). Concordance was  74.0% in the 25–34 years old group, but
just 50.5% among those aged <15 years.The sensitivity of vaccination and infection history as a predic-
tor of seropositivity was  75.8%. The PPV was 79.9%. However, the
speciﬁcity and NPV were 10.3% and 8.3%, respectively. Amongst
J.A. Polonsky et al. / Vaccine 33 (2015) 4554–4558 4557
Table  4
Sensitivity, speciﬁcity, positive predictive value and negative predictive value of reported measles protection compared to serological.
Participants* Sensitivity (%) Speciﬁcity (%) Positive predictive value (%) Negative predictive value (%)
<35 years (n = 661) 75.8 10.3 79.9 8.3
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t<15  years (n = 91) 93.8 2.3
* Excluding unknown protection status by history.
articipants <15 years of age, sensitivity was 93.8%, but again, speci-
city, PPV and NPV value were poor (Table 4).
. Discussion
The majority of participants included in this study were sero-
rotected against measles and this increased with age. Amongst
articipants <35 years of age, who had opportunities for measles
accination, only 77% of those that declared previous vaccination
ere seropositive. This was lower amongst the young. In this study,
eported vaccination and previous infection were poor predictors
f seropositivity. Age and gender were the main factors associated
ith seroprotection, with older age and female gender associated
ith higher odds of seropositivity.
A similarly high seroprotection amongst an adult population
as found in a study in Kenya, among whom infection or viral
xposure was postulated to have likely contributed to the high
ntibody levels seen amongst older age groups [9]. Indeed, in this
tudy GMTs were signiﬁcantly higher amongst those that declared a
ecent measles infection within their household, indicating a boost
n IgG antibodies induced by anamnestic response.
Measles vaccine efﬁcacy for a single dose in similar settings has
een estimated at approximately 84% [24]. In our study, this imper-
ect vaccine efﬁcacy may  have led to an underestimation of the
rue discordance between vaccination status and seroprotection,
s a proportion of those reporting having been vaccinated would
ot have been immunized by the vaccination. Assuming all study
articipants reporting having been vaccinated would have received
ust one dose, this would suggest an expected 1001 (84% of 1192)
mmunized participants, which is more discordant than the 1772
bserved to be seroprotected (immunized). However, as second
nd third doses greatly improve measles vaccine efﬁcacy, the true
roportion immunized by vaccination may  have been substantially
reater than 84%.
Some studies have investigated the validity and reliability of
elf-reported vaccination status against measles and other anti-
ens. A recent systematic review [10] of the validity of vaccination
ards and parental recall in estimating vaccination coverage iden-
iﬁed ﬁve studies conducted in low and middle income countries,
f which just one was from Africa (Guinea-Bissau) [11]. Our results
re in a similar range to those reported among low-middle income
ountries in this systematic review, which reported median con-
ordance of 54%, median sensitivity and speciﬁcity of 53% and 69%,
espectively, and median PPV and NPV of 94% and 13%, respectively.
Among other antigens, reported inﬂuenza vaccination status
as reported to be a generally highly sensitive measure of vaccina-
ion status, but had variable speciﬁcity [12–16]. In three studies,
eported pneumococcal polysaccharide vaccination status was
eported to have high sensitivity and speciﬁcity [14,17,18], while
nother study reported high sensitivity but poor speciﬁcity of this
easure [15]. Reported HPV vaccination status was shown to have
 high sensitivity and speciﬁcity relative to provider-reported vac-
ination status among adolescent females in the USA [19], while
nother study reported high levels of inaccuracy between self-
eported and actual vaccination status [20].
These results must be interpreted with caution, particularly as
he great majority of participants were adults, potentially leading
o substantial recall bias and/or misclassiﬁcation due to the long51.7 25.0
time between vaccination and recall. Therefore, these results apply
primarily to adults in similar settings, and further studies would be
required for better understanding of such effects among children
and younger adults, at whom measles vaccination strategies are
generally targeted.
A high proportion of participants declared being vaccinated
against measles. This was even the case for older participants that
were less likely to be targeted by vaccination activities. It is likely
that vaccination status was  not correctly identiﬁed for part of these
participants. Moreover, a relatively low number of participants
reported having had a measles infection. This is particularly sur-
prising amongst older participants, born before widespread use of
vaccination where, with circulating virus, much of the population
would have been infected by a young age [7]. Measles vaccination
and infection generally occur early on in life and there may  have
been problems with accurate recall, particularly among the older
study participants.
The low immunity found in children <15 years of age in this
study is surprising, especially because the study was conducted
soon after a reactive mass vaccination campaign that reached high
vaccination coverage. Similar protection levels were also found in
a seroprevalence study in Bangui, Central African Republic, despite
high reported vaccination coverage [8]. The selection of study par-
ticipants in these studies might have played a role as both studies
included a high proportion of children recruited at clinic visits,
which may  have introduced selection bias in the sample, with an
increased probability of selecting sick or unvaccinated children.
Furthermore, vaccination cards were only available for a small
minority and vaccination status might have been overestimated.
Another limitation of this study is that we used ELISA for deter-
mining measles IgG antibody titres, which has been shown to be
both sensitive and speciﬁc [21,22]. However, PRNT is the gold-
standard test [23], but is much more expensive, requires specialised
training, and was  not available at NICD at the time of study imple-
mentation. While not as sensitive and speciﬁc as PRNT, ELISA is the
most commonly used test for determining measles antibody titres.
In conclusion, the results of the study presented here have
important implications for measles control programs. As the cor-
relation between reported vaccination and seroprotection was
weaker than expected, reported vaccination and/or infection status
may  be an unreliable indicator of seroprotection status. In sett-
ings implementing measles control and elimination strategies, or
in which measles outbreaks arise, it may  be worthwhile to conduct
similar serosurveys, as systematic overestimation of the propor-
tion of seroprotected children could have major ramiﬁcations if
used to guide vaccination strategies. This information can help to
guide control programs in order to ensure that progress in measles
control continues.
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